Genetic Agency Technology Conference (GATC) 2026
A one-day gathering where patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers come together to co-create the future of genetic medicine
Hyatt Regency San Francisco Airport
About GATC
We are working to build a world with “genetic agency”: an individual’s ability to take action at the genetic level to live a healthier life. It’s a term we introduced to highlight the importance of creating therapeutic options where none exist today, and to recognize the efforts of patients and their families who work to develop these medicines themselves rather than to give up hope. To further the momentum, Dyno is hosting the 2nd Genetic Agency Technology Conference (GATC) in San Francisco on November 18.
The conference is inspired by a vision of the future with patient-empowering genetic technologies that are safe, effective and accessible to all – and the recognition that we will need to overcome major challenges, technological and otherwise, for all of these treatments to become a reality. This future can’t be realized by any one actor alone – it requires a community working together with pace to turn powerful emerging technologies into patient impact.
At GATC we’re bringing together leaders from various sectors: patients, AI pioneers, technologists, entrepreneurs, and therapeutic developers. Topics at this meeting will include patient stories, state of the art AI for sequence design, along with enabling genetic technologies, and other areas of interest to attendees such as preclinical development, manufacturing and regulatory pathways.
Compared to other conferences, GATC puts greater emphasis on technological frontiers, firmly grounded in patient impact and including highly participatory sessions emphasizing conversation and connection. Our assumption is that everyone who attends comes with expertise and a goal.
Why Attend
Empower
Hear from patients directly as co-creators shaping the next generation of genetic technologies
Connect
Meet your next collaborator and build lasting relationships across the gene therapy ecosystem, united by a shared commitment to genetic agency
Imagine
Step into the future with sessions that reveal the technology trends shaping what’s next
Activate
Leave with optimism and the conviction to act to realize a world with genetic agency
Featured Speakers
Our exciting lineup of speakers includes:
Alex Lenail, PhD
Postdoctoral Researcher at the Wyss Institute, Harvard Medical School
His father's adrenoleukodystrophy (ALD) diagnosis and the shelving of its only treatment set Alex on a mission to develop a gene therapy.
Andreas Borg
Founder at CURE5 Foundation and Full Stack Engineer at Jimini Health
Co-founded CURE5 Foundation after his daughter was diagnosed with CDKL5 Deficiency Disorder, and is applying his software engineering background to build AI tools that help families make decisions and accelerate therapeutic development.
Linde Jacobs, RN
Registered Nurse and Frontotemporal Dementia (FTD) Caregiver Advocate
After caring for and losing her mother to early-onset FTD-MAPT and facing the same inherited fate for herself and many in her family, Linde is racing to advance a gene therapy before the next generation is impacted.
Matt Wilsey
Chairman, President & Co-founder at Grace Science Foundation
Founded Grace Science after his daughter's NGLY1 deficiency diagnosis and advanced the disease’s first gene therapy into the clinic, treated his daughter in 2025 as part of a clinical program.
Stevie Ringel
Founder & CEO at Nome, President at Kizuna Foundation
Facing blindness from an ultra-rare KIZ gene mutation shared with his sister, Stevie founded Kizuna Foundation to develop a gene therapy to save their sight, and launched Nome.bio to use AI to make personalized therapeutics accessible to any rare disease family.
Dean Suhr
President & Cofounder at MLD Foundation
After two daughters were diagnosed with metachromatic leukodystrophy (MLD) in 1995, Dean co-founded the MLD Foundation, partnered with researchers to bring gene therapy Lenmeldy to FDA approval in 2024, and fought in parallel to add MLD to newborn screening.
Heidi Epstein
Vice Chair at Rett Syndrome Research Trust and Founder of Reverse Rett LA
When her 3 year old daughter Hannah was diagnosed with Rett syndrome in 2008, she was told a cure was impossible. Undeterred, Heidi joined the board of the Rett Syndrome Research Trust and founded Reverse Rett LA, now the world's largest Rett syndrome fundraiser. The event has played a critical role in helping to advance the field from basic science to two ongoing gene therapy trials.
Schedule
November 18, 2026
8am - 5pm
5pm - 8pm
FAQ
Interested in taking part in GATC 2026?
GATC is an invitation-only event, though a limited number of spots are available for those who apply to attend. We welcome anyone interested to submit an application no later than August 14th.
GATC 2025
Last November, the inaugural GATC brought together 200 carefully selected leaders in Boston, from patient advocates and drug developers to technologists and regulators. Speakers included Victoria Gray, George Church, Sonia Vallabh, Terence Flotte, Sylke Poehling, and Allyson Berent. The result was a day of stimulating conversation, new connections, and the energy to build a movement.